Novartis: 3 Key Takeaways for Long-Term Investors

Novartis raised its full-year 2026 core operating income guidance to in-line to low-single-digit growth after delivering 4% net sales growth in Q3 2026. The company is successfully offsetting patent expirations through sales of newly launched priority medicines, with Rhapsido peak sales guidance upgraded to over $4 billion. Operating margins are on track to reach 40% by 2029 as SG&A expenses fell 7% while maintaining top-line growth.